A copper-lowering strategy attenuates amyloid pathology in a transgenic mouse model of Alzheimer's disease

Joseph F. Quinn, Christopher J. Harris, Katherine E. Cobb, Christopher Domes, Martina Ralle, George Brewer, Teri L. Wadsworth

Research output: Contribution to journalArticlepeer-review

17 Scopus citations

Abstract

There is increasing evidence for the crucial role of metals in the pathology of Alzheimer's disease. Both the aggregation and neurotoxicity of amyloid-β are dependent on the presence of copper. This study investigated the ability of the copper-complexing drug tetrathiomolybdate to reduce amyloid-β pathology and spatial memory impairment in both a prevention and a treatment paradigm in the Tg2576 mouse model of Alzheimer's disease. Tetrathiomolybdate treatment lowered brain copper and reduced amyloid-β levels in the prevention paradigm, but not in the treatment paradigm. Our data suggests that controlled lowering of systemic copper may achieve anti-amyloid effects if initiated early in the disease process.

Original languageEnglish (US)
Pages (from-to)903-914
Number of pages12
JournalJournal of Alzheimer's Disease
Volume21
Issue number3
DOIs
StatePublished - 2010

Keywords

  • Alzheimer's disease
  • Tg2576
  • amyloid
  • copper
  • tetrathiomolybdate

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Psychology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'A copper-lowering strategy attenuates amyloid pathology in a transgenic mouse model of Alzheimer's disease'. Together they form a unique fingerprint.

Cite this